Revisiting the mechanisms of immune evasion employed by human parasites
M Chulanetra, W Chaicumpa - Frontiers in cellular and infection …, 2021 - frontiersin.org
For the establishment of a successful infection, ie, long-term parasitism and a complete life
cycle, parasites use various diverse mechanisms and factors, which they may be inherently …
cycle, parasites use various diverse mechanisms and factors, which they may be inherently …
Role of cytokines in experimental and human visceral leishmaniasis
Visceral Leishmaniasis (VL) is the most fatal form of disease leishmaniasis. To date, there
are no effective prophylactic measures and therapeutics available against VL. Recently, new …
are no effective prophylactic measures and therapeutics available against VL. Recently, new …
Global genome diversity of the Leishmania donovani complex
Protozoan parasites of the Leishmania donovani complex–L. donovani and L. infantum–
cause the fatal disease visceral leishmaniasis. We present the first comprehensive genome …
cause the fatal disease visceral leishmaniasis. We present the first comprehensive genome …
Antileishmanial drug discovery and development: time to reset the model?
AI Olias-Molero, C de la Fuente, M Cuquerella… - Microorganisms, 2021 - mdpi.com
Leishmaniasis is a vector-borne parasitic disease caused by Leishmania species. The
disease affects humans and animals, particularly dogs, provoking cutaneous …
disease affects humans and animals, particularly dogs, provoking cutaneous …
From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection
G Volpedo, RH Huston, EA Holcomb… - Expert review of …, 2021 - Taylor & Francis
Introduction Leishmaniasis is a major public health problem and the second most lethal
parasitic disease in the world due to the lack of effective treatments and vaccines. Even …
parasitic disease in the world due to the lack of effective treatments and vaccines. Even …
Applications of nanomaterials in leishmaniasis: a focus on recent advances and challenges
Leishmaniasis is a widely distributed protozoan vector-born disease affecting almost 350
million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but …
million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but …
Leishmaniasis in the United States: emerging issues in a region of low endemicity
JM Curtin, NE Aronson - Microorganisms, 2021 - mdpi.com
Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many
different species within the genus Leishmania, is an unfamiliar disease to most North …
different species within the genus Leishmania, is an unfamiliar disease to most North …
Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
Visceral leishmaniasis (VL), a vector-borne disease, is caused by an obligate
intramacrophage, kinetoplastid protozoan parasite of the genus Leishmania. Globally, VL is …
intramacrophage, kinetoplastid protozoan parasite of the genus Leishmania. Globally, VL is …
Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum
Visceral leishmaniasis (VL) or kala-azar, the most severe form of the disease, is endemic in
more than eighty countries across the world. To date, there is no approved vaccine against …
more than eighty countries across the world. To date, there is no approved vaccine against …
[HTML][HTML] Multifunctional, TNF-α and IFN-γ-Secreting CD4 and CD8 T Cells and CD8High T Cells Are Associated With the Cure of Human Visceral Leishmaniasis
LS Rodrigues, AS Barreto, LGS Bomfim… - Frontiers in …, 2021 - frontiersin.org
Visceral leishmaniasis (VL) is a chronic and often fatal disease caused by protozoans of the
genus Leishmania that affects millions of people worldwide. Patients with symptomatic VL …
genus Leishmania that affects millions of people worldwide. Patients with symptomatic VL …